Sf-RVN is an Sf-rhabdovirus-free S. frugiperda cell line that can seamlessly replace the widely used, but persistently virally contaminated Sf9 or Sf21 cell lines for recombinant protein or rAAV production.

Read the peer-reviewed paper describing Sf-RVN cells published in the Elsevier journal 'Protein expression and purification' 

Read another peer-reviewed paper published in the Elsevier journal 'Biologicals' about endogenous viral elements discovered by GlycoBac researchers in Sf-RVN and other cell lines.

GlycoBac provides Sf-RVN cells through our partner Millipore Sigma under commercial Materials Transfer Agreements (for evaluation) and/or licensing agreements (for application) in various fields of use. Please contact Dr. Jarvis directly for additional information.

Features of Sf-RVN cells include:
 
- No Sf-rhabdovirus contamination detectable by a highly sensitive nested RT-PCR assay over more than 100 continuous passages
 
- Growth rates in serum free medium identical to Sf9 
    Approximately 20 h doubling time in suspension culture in Expression Systems' ESF-921 medium without serum
 
- Recombinant protein productivity in serum free medium identical to Sf9 
    Tested for three recombinant proteins
 
- Higher baculovirus titers than Sf9 cells
    5 to 10-fold higher levels of infectious baculovirus progeny
 
- Better plaque assays than Sf9 cells
    Sf-RVN cells consistently produce larger, more distinct plaques in traditional plaque assays compared to Sf9 cells